Biotechnology
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

$187.3M

Market Cap • 12/25/2024

2021

(3 years)
Founded

2024

IPO

NASDAQ

Listing Exchange
Flag of US

Warren

Headquarters • New Jersey

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions
  • ...and much more!

    Get Premium